BioTE is not FDA approved. The company’s hormone pellets are compounded medications, which means they are custom-mixed by pharmacies rather than manufactured and tested through the FDA’s drug approval process. In 2017, the FDA issued a warning letter to BioTE Medical specifically stating that several of its products were “not generally recognized as safe and effective” and could not be legally marketed without prior FDA approval.
What BioTE Actually Is
BioTE is a hormone therapy company that provides subcutaneous pellets containing hormones like estradiol and testosterone. These pellets are inserted under the skin, typically in the hip area, and release hormones over several months. The company operates through a network of certified practitioners who order the pellets from compounding pharmacies and perform the insertion procedure in their offices.
The hormones used in BioTE pellets are often called “bioidentical,” meaning they are chemically identical to hormones your body produces naturally. This is an important distinction to understand, because the term “bioidentical” does not mean the same thing as “FDA approved.” Some bioidentical hormones are available in FDA-approved forms (patches, pills, creams), while others, like BioTE’s pellets, are compounded and have never gone through the FDA approval process.
The 2017 FDA Warning Letter
The FDA sent a formal warning letter to BioTE Medical in May 2017 targeting four specific products: BioTE DIM, BioTE Probiotic, BioTE Iodine Plus, and BioTE Omega 3. The agency stated that these products were “new drugs” under federal law that could not be legally introduced into interstate commerce without prior FDA approval. The warning was based on health claims BioTE made about these supplements, which crossed the line from general wellness marketing into therapeutic claims that would require FDA authorization.
This letter addressed BioTE’s supplement line rather than the hormone pellets themselves, but it highlights the broader regulatory gap. The hormone pellets fall into a different category, compounded drugs, which operate under their own set of rules and exemptions.
How Compounded Pellets Avoid FDA Approval
Compounded drugs occupy a legal gray area. Under federal law, pharmacies that register as “outsourcing facilities” under Section 503B can compound sterile drugs without obtaining individual FDA approval for each product. These facilities must follow good manufacturing practices and submit to FDA inspections, but the drugs themselves never go through the clinical trials that FDA-approved medications require.
This means BioTE pellets can be legally produced and used, even without FDA approval, as long as they’re compounded by a qualifying pharmacy. The tradeoff is significant: no large-scale clinical trials have been conducted to establish standardized dosing, long-term safety data, or consistent potency for these specific pellet formulations. Each batch can vary slightly depending on the compounding pharmacy that produces it.
What Medical Organizations Say
Major medical bodies have raised concerns about compounded hormone therapies like BioTE. A study commissioned by the FDA and conducted by the National Academies of Sciences, Engineering, and Medicine found “a lack of rigorous evidence of safety and effectiveness from well-designed or properly controlled clinical studies.” The report concluded that the widespread use of compounded bioidentical hormones poses a public health concern due to both the evidence gap and limited oversight.
The North American Menopause Society has flagged several specific risks with compounded hormone therapy: inconsistent dosing (too much or too little hormone in each pellet), potential impurities, lack of sterility guarantees, and the absence of a standardized label outlining risks. The American College of Obstetricians and Gynecologists echoes these concerns in its own clinical guidance.
None of these organizations say compounded hormones never work or are always dangerous. Their concern is that without the rigorous testing required for FDA approval, there’s no reliable way to confirm what patients are actually getting or predict how they’ll respond.
FDA-Approved Bioidentical Alternatives Exist
If the appeal of BioTE is the “bioidentical” aspect, it’s worth knowing that several FDA-approved products use the same hormones. Micronized progesterone, estradiol, and DHEA are all available in FDA-approved formulations delivered as pills, patches, gels, sprays, and vaginal inserts. These products have undergone clinical trials, carry standardized dosing, include detailed safety labeling, and are manufactured under strict quality controls.
The key difference between these approved products and BioTE pellets isn’t the hormone itself. It’s the delivery method and the level of regulatory oversight. Pellet implants offer convenience (typically replaced every three to six months), but once a pellet is inserted, the dose cannot be adjusted if side effects develop. With a patch or pill, you can simply stop taking it.
What “Not FDA Approved” Means for You
Lack of FDA approval doesn’t automatically mean a product is unsafe, but it does mean certain safeguards are missing. FDA-approved drugs come with a standardized label listing known side effects, drug interactions, and contraindications. They’ve been tested in controlled trials with enough participants to identify common adverse effects. Their manufacturing is tightly regulated to ensure each dose contains exactly what it claims.
Compounded products like BioTE pellets have none of these guarantees built in. The evidence supporting their use comes mostly from what the NASEM report described as “anecdotal claims, patient reports, and prescriber testimonies” rather than controlled clinical research. Many patients report feeling better on pellet therapy, but individual experience and clinical proof are different standards of evidence.
If you’re considering BioTE or already using it, the most practical step is understanding that you’re using a compounded product operating outside the FDA approval framework. That context matters when weighing the benefits you experience against the unknowns that remain.